INE168P01015
INE168P01015
EMCURE PHARMACEUTICALS L
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 80/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±35.4% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (-0.1x).
Beta (Market Relation)
-0.08x
DefensiveVolatility (3Y p.a.)
35.4% p.a.
FallbackMax Drawdown (3Y)
-40.7%
FallbackSharpe Ratio
0.33
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | +31.4% |
| 3 Years | 35.4% | -40.7% | 0.33 | — |
| 5 Years | — | — | — | — |
| 10 Years | — | — | — | — |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.